Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 16/20 | 0.59 |
| ▸ | KDM6B | O15054 | 9/20 | 0.59 |
| ▸ | KDM4D | Q6B0I6 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | KDM4A | O75164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | ASPH | Q12797 | 2/20 | 0.47 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.47 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.44 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82604 | 1.00 | KDM4C (0.59) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| Hydrochloric Acid SCHEMBL1027857 | 0.98 | KDM4C (0.57) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| Nitrous Acid SCHEMBL28904582 | 0.92 | KDM4C (0.52) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL8686759 | 0.88 | ROCK2 (0.47) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL229353 | 0.83 | KDM4C (0.53) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL30316868 | 0.83 | KDM4C (0.53) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL25201864 | 0.81 | KDM4C (0.42) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL459712 | 0.81 | LOXL2 (0.44) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL2618803 | 0.81 | TDP1 (0.55) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL724581 | 0.81 | ALDH1A1 (0.52) | KDM4CKDM6BKDM4DKDM4EKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118420919-A | Metal organic framework material with trivalent boron blocked Lewis acid-base pair with fixed structures at two ends, preparation method and application thereof | 武汉大学 | 2024-08-02 | — | — | CN | claimed |
| EP-4559915-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | Novartis AG (CH) | 2025-05-28 | — | — | EP | disclosed |
| US-12312353-B2 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NOVARTIS AG (CH) | 2025-05-27 | — | — | US | disclosed |
| EP-4013755-B1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2025-01-08 | — | — | EP | disclosed |
| WO-2024240108-A1 | ARYL UREA PARP1 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海海和药物研究开发股份有限公司 | 2024-11-28 | — | — | WO | disclosed |
| CN-114585622-B | Piperidinyl-methyl-purinamines as NSD2 inhibitors and anticancer agents | 诺华股份有限公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-118420919-A | Metal organic framework material with trivalent boron blocked Lewis acid-base pair with fixed structures at two ends, preparation method and application thereof | 武汉大学 | 2024-08-02 | — | — | CN | disclosed |
| EP-4263501-A1 | KINASE INHIBITORS AND USES THEREOF | ABM Therapeutics Corporation (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-4143195-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | Janssen Pharmaceutica NV (BE) | 2023-03-08 | — | — | EP | disclosed |
| US-20230002388-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-4076459-A1 | PRMT5 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2022-10-26 | — | — | EP | disclosed |
| US-11420970-B1 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NOVARTIS AG (CH) | 2022-08-23 | — | — | US | disclosed |
| WO-2022133040-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORPORATION (US) | 2022-06-23 | — | — | WO | disclosed |
| EP-4013755-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | Novartis AG (CH) | 2022-06-22 | — | — | EP | disclosed |
| EP-4007638-A1 | PYRIDINE DERIVATIVES AS KIF18A INHIBITORS | Amgen Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| CN-114585622-A | Piperidinyl-methyl-purinamines as NSD2 inhibitors and anticancer agents | 诺华股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12312353-B2 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NSD2, NSD1, NSD3 | KDM4C 1339/4885KDM6B 659/4885KDM4D 683/4885 |
| US-11420970-B1 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NSD2, NSD1, NSD3 | KDM4C 1339/4885KDM6B 659/4885KDM4D 683/4885 |
| US-20230002388-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | NSD2, NSD1, NSD3 | KDM4C 1339/4885KDM6B 659/4885KDM4D 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.